title: Potentiation of antitumor effects of tumor necrosis factor alpha and interferon gamma by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice.
abstract: The efficacy of systemic infusion of recombinant human macrophage-colony-stimulating factor (M-CSF) in combination with local treatment with human recombinant tumor necrosis factor (TNF) alpha and mouse recombinant interferon (IFN) gamma was studied in vivo on a subclone of B16 melanoma (MmB16) in mice. Short-term intravenous administration of M-CSF at a dose of 10(6) units daily had no antitumor effect in vivo. Similarly, local treatment of tumor with TNF alpha (5 micrograms daily) did not produce any therapeutic effect. However, simultaneous administration of the same dose of TNF alpha with IFN gamma (1000 units daily) resulted in a synergistic effects manifested by the retardation of tumor growth. Addition of systemic infusion of M-CSF to the local therapy with TNF alpha and IFN gamma induced further augmentation of antitumor efficacy and delayed progression of MmB16 melanoma. The strengthened antitumor effect of combination therapy including M-CSF, TNF alpha and IFN gamma was most probably due to the increased release of monocytes from the bone marrow, their recruitment into the site of tumor growth and subsequent local stimulation of their antitumor activity.
authors.affiliation: Department of Immunology, Medical School of Warsaw, Poland.
authors.forename: W
authors.initials: W
authors.lastname: Lasek
authors.forename: A
authors.initials: A
authors.lastname: Wańkowicz
authors.forename: K
authors.initials: K
authors.lastname: Kuc
authors.forename: W
authors.initials: W
authors.lastname: Feleszko
authors.forename: J
authors.initials: J
authors.lastname: Gołab
authors.forename: A
authors.initials: A
authors.lastname: Giermasz
authors.forename: W
authors.initials: W
authors.lastname: Wiktor-Jedrzejczak
authors.forename: M
authors.initials: M
authors.lastname: Jakóbisiak
mesh_terms: D000818:Animals; D001853:Bone Marrow / Q000187:drug effects; D018450:Disease Progression; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000494:pharmacology / Q000627:therapeutic use*; D016173:Macrophage Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008546:Melanoma, Experimental / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009000:Monocytes / Q000502:physiology; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D007155:Immunologic Factors; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D016173:Macrophage Colony-Stimulating Factor; D007371:Interferon-gamma